{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:52:51Z","timestamp":1782906771393,"version":"3.54.5"},"reference-count":17,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Facility-level availability of Japanese Society of Medical Oncology (JSMO) specialists may influence care processes, but national cancer genomic medicine data rarely capture patient-level specialist involvement. We conducted a nationwide retrospective analysis of pancreatic cancer cases in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT). The primary exposure was facility-level registry-listed JSMO specialist count (0\u20131 vs. \u22652 specialists), with \u22652 interpreted as a proxy for minimum plural specialist-team availability. The primary endpoint was time from systemic therapy start to recorded first-line treatment end. The primary cohort included 14,568 patients at 261 facilities. Median recorded first-line treatment-process duration was 5.7 months in the 0\u20131 specialist group and 6.4 months in the \u22652 specialist group. In the clinical plus facility-adjusted Cox model, \u22652 specialist availability was associated with a lower hazard of recorded first-line treatment end (HR 0.895, 95% CI 0.810\u20130.988; p = 0.028). Supportive overall survival findings did not indicate a survival advantage, reinforcing the operational nature of the primary endpoint. These findings indicate a facility-level association with an operational treatment-process endpoint, not patient-level specialist involvement, treatment efficacy, survival benefit, facility ranking, or causality. Chemotherapy-specific national database elements are needed to evaluate specialist contribution directly.<\/jats:p>","DOI":"10.3390\/curroncol33070393","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:19:02Z","timestamp":1782893942000},"page":"393","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-5130","authenticated-orcid":false,"given":"Shinya","family":"Kajiura","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama 930-0194, Japan"},{"name":"JSMO Secretariat Division, Japanese Society of Medical Oncology, Tokyo 105-0013, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-6803","authenticated-orcid":false,"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[{"name":"JSMO Secretariat Division, Japanese Society of Medical Oncology, Tokyo 105-0013, Japan"},{"name":"Department of Medical Oncology, Kochi Medical School, Kochi University, Nankoku 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4205-9540","authenticated-orcid":false,"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1097\/MPA.0000000000002600","article-title":"Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis","volume":"55","author":"Abe","year":"2026","journal-title":"Pancreas"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.5306\/wjco.v12.i9.787","article-title":"Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer","volume":"12","author":"Blomstrand","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105826","DOI":"10.1016\/j.esmoop.2025.105826","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer","volume":"10","author":"Tai","year":"2025","journal-title":"ESMO Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1634\/theoncologist.2016-0447","article-title":"Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer","volume":"22","author":"Abrams","year":"2017","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40801-018-0137-x","article-title":"Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting","volume":"5","author":"Cartwright","year":"2018","journal-title":"Drugs Real. World Outcomes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3892\/mco.2023.2694","article-title":"Real-world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real-world data project","volume":"19","author":"Shimoyama","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/jjco\/hyab135","article-title":"Current status of medical oncology in Japan and changes over the most recent 7-year period: Results of a questionnaire sent to designated cancer care hospitals","volume":"51","author":"Arai","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2183\/pjab.96.023","article-title":"Cancer genomic medicine in Japan","volume":"96","author":"Mano","year":"2020","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/cas.14754","article-title":"Establishment and implementation of Cancer Genomic Medicine in Japan","volume":"112","author":"Mukai","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Benchimol, E.I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., S\u00f8rensen, H.T., von Elm, E., and Langan, S.M. (2015). The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001885"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Seguchi, K., Hashimoto, T., Fujisawa, T., Shibuki, T., Morizane, C., Nonomura, N., Iwata, H., Watari, H., Okano, S., and Namikawa, K. (2026). Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: Evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study. Int. J. Clin. Oncol.","DOI":"10.1007\/s10147-026-03069-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10147-014-0757-4","article-title":"Cancer registries in Japan: National Clinical Database and site-specific cancer registries","volume":"20","author":"Anazawa","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1111\/cas.15837","article-title":"Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers","volume":"114","author":"Hagio","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1111\/cas.16329","article-title":"Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications","volume":"115","author":"Doi","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41591-025-04086-8","article-title":"Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors","volume":"32","author":"Saito","year":"2026","journal-title":"Nat. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/393\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:34:01Z","timestamp":1782905641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070393"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070393","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}